TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQX: ATBPF), a diversified biotechnology company is providing an update on the clinical development program for ATB-346, its lead drug candidate targeting the global need for a safer remedy for chronic pain and inflammation.
Antibe Engages Topstone Research Inc.
Antibe’s upper GI safety study planned to commence next quarter will be a double-blind, active comparator (naproxen) trial, and will be conducted in 240 healthy volunteers. The primary endpoint will be endoscopically detected ulceration. The study is designed to demonstrate the unequivocal GI-safety superiority of ATB-346 over naproxen, the most-prescribed NSAID in North America. Antibe has engaged Topstone Research Inc. (“Topstone”), a well-respected clinical research organization (“CRO”) based in Toronto, Canada to manage this Phase 2 study. Topstone acted as CRO for the initial Phase 2 efficacy study of ATB-346 that was successfully completed last August with strong results.
Dr. Francis Chan, a leading gastroenterologist with extensive NSAID clinical trial expertise, to support Phase 2 GI safety clinical study
Antibe is pleased to announce that Dr. Francis Chan will serve as a key advisor in the upcoming Phase 2 GI safety study for ATB-346. Dr. Francis Chan is the Dean of Medicine at the Chinese University of Hong Kong and one of the most recognized and respected gastroenterologists in the world. Dr. Chan has particular expertise in the area of GI damage and bleeding caused by NSAIDs, and was the lead investigator of several very large, landmark clinical trials of Celebrex (which became the NSAID market leader by dollar volume at approximately $3 billion/year until patent expiry). Dr. Chan has published extensively in some of the world’s leading medical journals, including the New England Journal of Medicine and The Lancet.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.